Jonathan Lambert
Jonathan Lambert is a correspondent for NPR's Science Desk, where he covers the wonders of the natural world and how policy decisions can affect them.
Lambert has been covering science, health and policy for nearly a decade. He was a staff writer at Science News and Grid. He's also written for The Atlantic, National Geographic, Quanta Magazine and other outlets, exploring everything from why psychedelics are challenging how people evaluate drugs to how researchers reconstructed life's oldest common ancestor. Lambert got his start in science journalism answering vital questions from curious kids, including "Do animals fart?" for Brains On, a podcast from American Public Media. He interned for NPR's Science Desk in 2019 where he wrote about the evolutionary benefits of living close to grandma and racial gaps between who causes air pollution and who breathes it.
Lambert earned a Master's degree in neurobiology and behavior at Cornell University, where he studied the unusual sex lives of Hawaiian crickets. [Copyright 2025 NPR]
-
To save the lives of infants and small kids in lower resource countries, there are a handful of tools: anti-malarial drugs, bed nets and vaccines. A massive experiment in rural Kenya suggests another. -
The mosquito-borne disease is sweeping through a province in southern China, which is taking strict measures to quash the outbreak. -
This man in Mozambique is one of many who've received a cash sum with no strings attached. The Trump administration has criticized and curtailed the practice. Advocates are pushing back with evidence. -
A new study reports on a novel way to short-circuit the parasite that spreads the disease so people wouldn't get infected with a mosquito's bite. -
Large scavengers like vultures and hyenas do an important job in protecting human health. But studies show these creatures are on the decline, allowing for the emergence of disease. -
A new study looks at lives saved by USAID in the past and what the future without the agency will look like. -
A drug called lenacapavir, administered in two injections a year, offers protection from HIV comparable to daily pills. One looming question: Will it be affordable for lower resource countries? -
Global health specialists talk about the consequences of the full or partial ban on travel to the U.S. from 19 countries. -
On May 30, a team of researchers funded by the National Institutes of Health got the word: Funding for their vaccine development program will end next year. -
These colorful snakes aren't just works of art. Erected for the World Health Assembly, they're meant to draw attention to an extremely neglected health issue: snakebite.
